HealthVerity, a data management provider helping clinicians and pharmaceutical and insurance companies manage health info of patients, raises $100M Series D
A massive database of real-world evidence—encompassing hundreds of millions of electronic records, lab test results …
Context & Ripple Effects
HealthVerity's $100M Series D lands in a funding lane that has been accelerating for two years: Verana Health raised $100M in early 2020 on anonymized patient registries for drug development, and months later Datavant took $40M at Series B to connect health datasets under privacy protections.
The round also extends a pattern of rising checks: Evidation Health raised $153M in March 2021 at a reported $1B-plus valuation after a smaller $45M Series D a year prior — so HealthVerity's nine-figure round is now table stakes rather than an outlier in real-world health data.
First-order effects
- HealthVerity gets capital to scale a database spanning hundreds of millions of electronic records and lab results, deepening its position with the three buyer groups it already serves: clinicians, pharmaceutical companies, and insurers.
Second-order effects
- Pharmaceutical companies evaluating real-world evidence vendors now weigh HealthVerity against well-funded rivals like Verana and Datavant, pushing competition toward data breadth and interoperability rather than price alone.
Third-order effects
- If successive large rounds across HealthVerity, Verana, Datavant, and Evidation hold, real-world evidence infrastructure consolidates into a distinct industry layer between providers and drug developers — with strategic investors like corporate VCs likely to follow once one platform becomes the default record source.
The trend: Capital is consolidating around real-world health data platforms as the standard substrate for clinical trials and drug development, with round sizes escalating from tens to hundreds of millions since 2018.